$XAIR Income Statement | Understand Stock

$XAIR

$2.21 +$0.07 (3.27%) Close

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2026 12 months to Mar 31, 2026	FY2025 12 months to Mar 31, 2025	FY2024 12 months to Mar 31, 2024	FY2023 12 months to Mar 31, 2023	FY2022 12 months to Mar 31, 2022
Revenues
Cost of revenues
Gross profit (loss)
Operating expenses:
Research and development
General and administrative
Settlement expense contingent on FDA approval
Milestone expenses incurred upon regulatory approval
Selling, general and administrative
Total operating expenses

Loss from operations
Other income/(expense):
Dividend and interest income
Dividend/investment income
Interest and finance expense
Change in fair value of warrant liability
Change in fair value of derivative liability
Estimated contingent loss
Other expense
Foreign exchange loss
Loss on extinguishment of debt
Loss on disposal/impairment of fixed assets
Other income/(expense)
Total other income/(expense)
Loss before income taxes
Net loss
Less: net loss attributable to non-controlling interest
Net loss attributable to Beyond Air, Inc.
Foreign currency translation adjustment
Comprehensive loss attributable to Beyond Air, Inc.
Net basic loss per share attributable to Beyond Air, Inc.
Net diluted loss per share attributable to Beyond Air, Inc.
Weighted average number of shares of common stock outstanding - basic
Weighted average number of shares of common stock outstanding - diluted

Comments